| 李秀英,张 勇,冯旭东,叶 青,付 阳.调强放疗联合替莫唑胺对高级别脑胶质瘤术后患者免疫功能和生活质量的影响[J].现代生物医学进展英文版,2021,(16):3187-3191. |
| 调强放疗联合替莫唑胺对高级别脑胶质瘤术后患者免疫功能和生活质量的影响 |
| Effect of Intensity Modulated Radiation Therapy Combined with Temozolomide on Immune Function and Quality of Life of Patients with High Grade Glioma after Operation |
| Received:February 05, 2021 Revised:February 28, 2021 |
| DOI：10.13241/j.cnki.pmb.2021.16.038 |
| 中文关键词: 调强放疗 替莫唑胺 高级别脑胶质瘤 术后 免疫功能 生活质量 |
| 英文关键词: Intensity modulated radiation therapy Temozolomide High grade glioma After operation Immune function |
| 基金项目:云南省自然科学基金面上项目（2016FB150） |
|
| Hits: 720 |
| Download times: 392 |
| 中文摘要: |
| 摘要 目的：观察调强放疗联合替莫唑胺对高级别脑胶质瘤术后患者免疫功能和生活质量的影响。方法：选择我院2015年7月~2017年9月收治的有完整临床资料的高级别脑胶质瘤患者107例，根据双色球随机分组法将患者分为对照组和观察组，分别为53例和54例，对照组给予调强放疗，观察组给予调强放疗联合替莫唑胺治疗，均治疗6周。对比两组疗效、免疫功能、生活质量、无进展生存时间、总生存时间和不良反应发生情况。结果：治疗6周后，观察组的客观缓解率55.56%、疾病控制率77.78%高于对照组的35.85%、56.60%（P<0.05）。观察组的无进展生存时间、总生存时间长于对照组（P<0.05）。治疗6周后，观察组的CD8+水平低于对照组，CD3+、CD4+水平高于对照组（P<0.05）。治疗6周后，观察组的躯体功能、机体疼痛、健康状况、生命力、心理职能、躯体角色、情感角色、社会功能维度评分高于对照组（P<0.05）。两组不良反应总发生率对比无显著性差异（P>0.05）。结论：调强放疗联合替莫唑胺应用于高级别脑胶质瘤术后患者，可减轻调强放疗导致的免疫抑制，提高患者生活质量，延长其无进展生存时间、总生存时间。 |
| 英文摘要: |
| ABSTRACT Objective: To observe the effect of intensity modulated radiation therapy combined with temozolomide on immune function and quality of life in patients with high grade glioma after operation. Methods: 107 cases of patients with high grade glioma with complete clinical data in our hospital from July 2015 to September 2017 were selected. According to the double chromosphere randomization, the patients were divided into control group and observation group, 53 cases and 54 cases, respectively. The control group was given intensity modulated radiation therapy, and the observation group was given intensity modulated radiation therapy combined with temozolomide, all patients were treated for 6 weeks. The efficacy, immune function, quality of life, progression free survival time, overall survival time and adverse reactions were compared between the two groups. Results: 6 weeks after treatment, the objective remission rate and disease control rate in the observation group were 55.56% and 77.78%, respectively, which were higher than 35.85% and 56.60% in the control group (P<0.05). The progression free survival time and overall survival time in the observation group were longer than those in the control group (P<0.05). 6 weeks after treatment, the level of CD8+ in the observation group was lower than that in the control group, and the levels of CD3+, CD4+ in the observation group were higher than those in the control group (P<0.05). 6 weeks after treatment, the dimensional scores of physical function, body pain, health status, vitality, psychological function, physical role, emotional role and social function in the observation group were higher than those in the control group (P<0.05). There was no significant difference in the total incidence rate of adverse reactions between the two groups (P>0.05). Conclusion: Intensity modulated radiation therapy combined with temozolomide for patients with high grade glioma after operation, can reduce the immunosuppression induced by intensity modulated radiation therapy, improve the quality of life, prolong the progression free survival time and overall survival time. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
